Emergent Biosolutions IncEBS
Price$6.37Intrinsic value$8.7838% above price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $770.2M-26.2% YoYTTM through 30 Jun 2026
Net Income -$176.8MTTM through 30 Jun 2026
Free Cash Flow $85.9MTTM through 30 Jun 2026

Margins

Current
Gross Margin39.2%
EBITDA Margin3.7%
Operating Margin6.7%
Net Margin-23.0%

Returns

1.3%ROE
-0.7%ROA

Balance Sheet Health

Debt / Equity1.10x
Current Ratio5.42x
Net Debt$429.4M
Cash & Equivalents$139.7M

Quality Metrics

Altman Z-Score0.93
Piotroski F-Score4 / 9
FCF Margin11.2%
Earnings-Beat Rate75.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $742.9M
Diluted EPS-$3.41TTM
'19'20'21'22'23'24'25
FY2025: $0.93

Dividend

No dividend

Capital Allocation

R&D Spend$45.3M
Capex Intensity1.5%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.